Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 122

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 122
---
 with the Merger Agreement will generate value for stockholders; |

| ● | the Company’s ability to maintain compliance with Nasdaq listing requirements; |

| ● | the expectations surrounding the potential safety, efficacy, and regulatory and clinical progress of the Company’s product candidates, including TTI-101 and TTI-109, and anticipated milestones and timing therefor; |

| ● | the Company’s plans to develop and commercialize its product candidates or any potential future product candidates; |

| ● | the potential results of preclinical studies and clinical trials and future regulatory and development milestones for the Company’s product candidates or any potential future product candidates; |

| ● | the performance of third-party manufacturers, clinical research organizations, and other vendors; |

| ● | the size and growth of the potential markets for the Company’s product candidates; |

| ● | the rate and degree of market acceptance of any other future approved indications or products; |

| ● | the Company’s ability to obtain and maintain additional regulatory approval of its product candidates or any future product candidates, and the labeling under any approval the Company may obtain; |

| ● | the Company’s ability to maintain existing and establish additional collaborations for its product candidates or future product candidates; |

| ● | the continued service of the Company’s key scientific or management personnel; |

| ● | the Company’s ability to establish commercialization and marketing capabilities for any future approved products; |

| ● | regulatory developments in the United States and foreign countries; |

67

| ● | the Company’s ability to obtain and maintain coverage and adequate reimbursement from third-party payers and governments for any other future approved indications or products; |

| ● | the Company’s planned use of its cash and cash equivalents and the clinical milestones it expects to fund with such proceeds; |

| ● | the accuracy of its estimates regarding expenses, future revenues and capital requirements; |

| ● | the Company’s ability to obtain funding for its operations; |

| ● | the Company’s ability to obtain and maintain intellectual property protection for its product candidates or future product candidates and the Company’s ability to operate its business without infringing on the intellectual property rights of others; |

| ● | the Company’s ability to maintain proper and effective internal controls over financial reporting and to remediate and prevent material weaknesses in the Company’s internal controls; |

| ● | the success of competing drugs that are or may become available; and |

| ● | the potential effects of any global health crises, geopolitical tensions and macroeconomic conditions on its business, operations, and